Back Home About Us

Positively Trans Survey Looks at Lives of Transgender People Living with HIV

The Transgender Law Center (TLC) released in March the first report of findings from its Positively Trans survey, which aims to learn more about the lives and experiences of transgender people living with HIV.TLC, working with a national advisory board of trans community leaders and with support from the Elton John AIDS Foundation, launched the survey in response to the structural inequities that drive the high rate of HIV/AIDS and poor health outcomes among trans people.

alt

Read more:

California Demonstration Projects to Study HIV PrEP for Transgender People

The California HIV/AIDS Research Program has announced funding for 3 new pre-exposure prophylaxis (PrEP) demonstration projects that will explore the use of Truvada (tenofovir/emtricitabine) for HIV prevention for transgender women and men, with a focus on improving adherence and monitoring interactions between antiretrovirals and gender-affirming hormone therapy.

alt

Read more:

April 10 is National Youth HIV and AIDS Awareness Day

April 10 is National Youth HIV and AIDS Awareness Day (NYHAAD), an opportunity to promote education and raise awareness about the epidemic among young people in the U.S. According to the Centers for Disease Control and Prevention (CDC), youth age 13 to 24 accounted for just over a quarter of all new HIV infections in 2010 -- rising to nearly 40% if those up to age 29 are included -- with an especially high burden among young gay and bisexual black and Latino men.

alt

Read more:

Opt-Out HIV, HBV, and HCV Testing in Emergency Departments Identifies Many New Infections

A week-long pilot study involving 9 U.K. emergency departments has shown that routine opt-out testing for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) can identify a significant number of previously undiagnosed infections, according to study results published in the March edition of HIV Medicine.

alt

Read more:

FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' Descovy, a new combination pill containing tenofovir alafenamide (TAF), which is easier on the kidneys and bones than the older tenfovir disiproxil fumarate (TDF) version. The new coformulation is similar to Truvada, but it has been approved only for use as a component of HIV treatment, not for pre-exposure prophylaxis or PrEP.

alt

Read more:

CROI 2016: Studies Probe Retention in Care for HIV+ Women Who Start ART During Pregnancy

Engaging lay counselors to provide a combination package of evidence-based interventions in Nyanza, Kenya, and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ program improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) show.

alt

Read more:

CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention

Merck's MK-8591, n investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

Read more:

Gene Therapy Snips HIV Out of Infected Cells and Makes Uninfected Cells Resistant

For the first time, researchers have used a gene-editing technique related to one already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed to remove HIV genes completely from infected cells, as shown by reductions in the cells' overall rate of HIV production. In cells not already infected, the therapy has itself become part of their genome, producing cells that are resistant to infection for a prolonged period, according to a report in a recent edition of Nature Scientific Reports.

alt

Read more:

CROI 2016: Partner Notification of HIV Status Is Feasible and Effective In African Settings

Partner notification programs, offering testing to the sexual partners of people newly diagnosed with HIV, have rarely been implemented in African countries, but can be highly effective there, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)show. A randomized study in Kenya found that partner notification services were able to test 42% of partners mentioned, increasing testing rates 4-fold.

alt

Read more: